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Association between Clinical Characteristics and Pathologic Nodal Stage in 
Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor 
Receptor 2-Negative (HER2-) Breast Cancer
Table 1: Summary of clinicopathologic characteristics of patients with positive LNs on ALND
• Chi-square analysis revealed no 
statistically significant association (p > 
0.05) between number of 
pathologically positive LNs and 
histology, race, hormone receptor 
expression, histologic grade, or LN 
palpability on a physical exam.
• Pearson's correlation test revealed no 
statistically significant association 
between pathologically positive LNs 
and median age, tumor size, or size of 
index LN found on preoperative US.
• US prediction of >3 LNs on ALND has 
a false negative rate of 96.6%.
• Only 2 patients had >3 suspicious LNs 
identified on US compared to 59 
patients with >3 truly positive LNs.
Table 3: Association between US nodal burden and nodal features on US and pathology
Conclusion
• Preoperative US to determine extent 
of LN involvement has a high false 
negative rate when confirmed by 
ALND.
• Individual clinicopathologic 
features cannot be used to 
predict the extent of LN involvement in 
ALND. Multivariate studies are in 
progress to evaluate whether 
these clinicopathologic features can 
be used in combination to 
predict the extent of axillary nodal 
involvement.
Limitations
• This study was limited due to the 
scope of analyses.
• Small sample size may have 
precluded identification of meaningful 
associations.
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1 LN on ALND​ 2 LN on ALND​ 3 LN on ALND​ >3 LN on ALND​
Total (n=157​) n=42​ n=33​ n=23​ n=59​
Median Age [years (range)]​ 59 (36-88)​ 60 (30-81)​ 54 (31-84)​ 58 (33-86)​
Mean Tumor Size [cm (range)]​ 2.93 (1.10-7.00)​ 2.92 (0.80-4.50)​ 2.80 (1.10-4.00)​ 2.78 (0.70-5.00)​
Histology​ (n=152)
IDC​ (n=113) 28​ (25)​ 25​ (22)​ 16​ (14)​ 44​ (39)​
ILC​ (n=30) 8​ (27)​ 5​ (17)​ 7​ (23)​ 10​ (33)​
Other​ (n=9) 6 (67)​ 3​ (33)​ 0​ (0)​ 0 (0)​
Histologic Grade​ (n=158)
1​ (n=17) 6 (35)​ 2​ (12)​ 4​ (24)​ 5​ (29)​
2​ (n=105) 27​ (26)​ 23​ (22)​ 16​ (15)​ 39​ (37)​
3​ (n=36) 9​ (25)​ 9​ (25)​ 3​ (8)​ 15​ (42)​
Molecular Classification (n=86)​
Luminal A (n=58)​ 16​ (28)​ 11​ (19)​ 10​ (17)​ 21​ (36)​
Luminal B (n=28)​ 9​ (32)​ 5​ (18)​ 2​ (7)​ 12​ (43)​
LVI​ (n=150)
% Identified (n=80) 16 (20) 11 (14) 16 (20) 37 (46)
% Not identified (n=70) 25 (36) 19 (29) 6 (8) 19 (27)
1-2 Suspicious LNs 
on US​
3+ Suspicious LNs 
on US​
Mean size index LN on US (cm)​ 1.71​ 1.94​
Median # positive LNs on ALND 2​ 3​
Mean largest LN metastasis on ALND (cm)​ 1.53​ 1.42​
Aim
• To analyze potential associations 
between clinicopathologic factors 
and number of pathologically 
positive LNs in patients with clinically 
axillary node-positive (cN1), 
HR+/HER2- BC who underwent 
upfront ALND.
Methods
• Patients with HR+, HER2-, cN1 BC 
who had undergone ALND were 
identified from MDACC patient 
records between 2002 and 2016.
• Clinical characteristics based on 
imaging and physical examination 
were examined and 
subsequently compared with 
pathology.
• Descriptive statistics were 
performed, and variables were 
assessed for association using 
Chi-square analysis and Pearson's 
correlation test.
Figure 1: Number of suspicious LNs on US
versus number of positive LNs on ALND
Figure 2: Number of pathologically positive LNs 





• The recently presented RxPONDER
trial demonstrated that 
postmenopausal patients with 
hormone receptor-positive 
(HR+), human epidermal growth factor 
receptor 2-negative (HER2-) breast 
cancer (BC) with 1-3 positive axillary 
lymph nodes (LN) and a low Oncotype 
DX Recurrence Score (≤25) 
may potentially forgo chemotherapy.​
• A method to accurately assess the 
extent of axillary LN involvement is 
needed.
• LN burden is typically determined 
through complete axillary lymph 
node dissection (ALND) for 
patients who are clinically node-
positive and undergoing 
upfront surgery.​
• ALND may be overtreatment 
for patients with limited axillary nodal 
burden.
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